- |||||||||| urelumab (BMS-663513) / BMS, Ono Pharma
Use of 4-1BB Agonist (Urelumab) during TIL Pre-REP promotes tumor-reactive like T cells (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_485; Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- |||||||||| Review, Journal: Safety considerations for drugs newly approved for treating acute myeloid leukemia. (Pubmed Central) - Oct 4, 2024
Since 2017, nine molecules were registered for newly-diagnosed AML: midostaurin, gilteritinib, quizartinib, enasidenib, ivosidenib, gemtuzumab ozogamycin, CPX-351, glasdegib, and venetoclax...However, in addition to their well-known cytotoxic activity, new molecules cause several unique, off-target toxicities. Also, potential drug-drug interactions (DDI) should be taken into consideration when choosing optimal first-line therapy; this remains a challenge in clinical practice.
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Roche
Review, Journal, IO biomarker: The role of antibody-based therapies in treating relapsed chronic lymphocytic leukemia. (Pubmed Central) - Oct 4, 2024 While immunotherapy is generally effective, some treatment failure can occur due to antigen loss, mutation, or down-regulation, and this remains the main obstacle to cure. The development of novel antibody therapies, including their combinations with targeted drugs and bispecific antibodies might help to reduce toxicity and improve efficacy.
- |||||||||| Imfinzi (durvalumab) / AstraZeneca
Review, Journal, Checkpoint inhibition: Association Between the Immune Checkpoint Inhibitor Durvalumab and Myasthenia Gravis: A Comprehensive Review. (Pubmed Central) - Oct 4, 2024 The clinical consequences of MG need meticulous monitoring, prompt identification, and suitable management to efficiently control the condition. Medical practitioners must carefully weigh the positive effects of ICIs against the possible hazards, emphasizing the necessity for more extensive investigation to improve patient results and establish uniform treatment protocols.
- |||||||||| Rituxan (rituximab) / Roche
Review, Journal: Aggressive Course of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): An Illustration of Two Cases and Review of Literature. (Pubmed Central) - Oct 4, 2024 After high-dose intravenous methylprednisolone (IVMP) and intravenous immunoglobulin (IVIG), she had full neurological recovery by the last follow-up...Treatment with IVMP led to minor improvement with discharge on steroid taper and azathioprine...Treatment throughout multiple admissions included intravenous steroids, IVIG, plasmapheresis, mycophenolate mofetil, and rituximab with minimal improvement, symptom recurrence, and progression of multifocal lesions...These cases had markedly different treatment responses despite similar baseline characteristics. The difference in morbidity and disability burden highlights the importance of further investigation of this condition through clinical trials.
- |||||||||| Kisqali (ribociclib) / Novartis
Clinical, Clinical data, Journal, Combination therapy, Real-world evidence, Real-world, Metastases: Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country. (Pubmed Central) - Oct 4, 2024 In real-world settings, and away from the stringency of controlled clinical trials, endocrine therapy in combination with ribociclib in patients with HR-positive/HER2-negative MBC is an effective and well-tolerated therapy with a manageable toxicity profile and a low drug discontinuation rate. Dose reduction due to toxicity did not worsen the outcome.
- |||||||||| Rituxan (rituximab) / Roche
Review, Journal: Rituximab in the Treatment of Non-Infectious Uveitis: A Review. (Pubmed Central) - Oct 4, 2024 These findings indicate that RTX may serve as an effective therapeutic option for NIU unresponsive to steroids and multiple immunotherapies. It may also warrant consideration as a potential first-line treatment in certain cases.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), ISA101 / ISA Pharma
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Oct 4, 2024 P2, N=18, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=50 --> 18 | Trial completion date: Jun 2027 --> Jun 2026 | Trial primary completion date: Jun 2027 --> Jun 2025
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
LENVATINIB, PEMBROLIZUMAB VERSUS CARBOPLATIN, PACLITAXEL IN PRETREATED, ADVANCED ENDOMETRIAL CANCER () - Oct 4, 2024 - Abstract #IGCS2024IGCS_651; Between January 2012 and September 2023, we identified 397 patients with PT-treated, advanced, or recurrent ECs who received lenvatinib plus pembrolizumab, and 469 patients receiving PT at a platinum-free interval of over 6 months. Following PSM, no significant difference in median OS was observed between the lenvatinib plus pembrolizumab and re-challenge PT groups (19
- |||||||||| Jemperli (dostarlimab-gxly) / GSK
IMPACT OF INVESTIGATOR-ASSESSED RESPONSE TO DOSTARLIMAB ON QUALITY OF LIFE IN THE RUBY TRIAL OF PRIMARY ADVANCED OR RECURRENT ENDOMETRIAL CANCER (PA/REC) (Auditiorium) - Oct 4, 2024 - Abstract #IGCS2024IGCS_54; P3 Among nonresponders, global QOL showed a similar trend between arms until C12; after C12, dostarlimab+CP showed improvements while placebo+CP showed a deterioration (Figure 2). For EQ-5D-5L, among responders, from C9 onward, dostarlimab+CP showed improved scores while placebo+CP showed a deterioration (C7 LSM [dostarlimab+CP vs placebo+CP], ?0.016 vs ?0.020; C13, 0.033 vs ?0.085); among nonresponders, scores deteriorated before C10 in both arms, and there was no clear trend beyond C10 (C7, ?0.093 vs ?0.043; C13, ?0.067 vs 0.086; C20, 0.
- |||||||||| Inlyta (axitinib) / Pfizer, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Trial completion date, Trial primary completion date, Surgery, Metastases: Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery (clinicaltrials.gov) - Oct 4, 2024 P2, N=84, Recruiting, For EQ-5D-5L, among responders, from C9 onward, dostarlimab+CP showed improved scores while placebo+CP showed a deterioration (C7 LSM [dostarlimab+CP vs placebo+CP], ?0.016 vs ?0.020; C13, 0.033 vs ?0.085); among nonresponders, scores deteriorated before C10 in both arms, and there was no clear trend beyond C10 (C7, ?0.093 vs ?0.043; C13, ?0.067 vs 0.086; C20, 0. Active, not recruiting --> Recruiting | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2024 --> Sep 2025
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Tecentriq (atezolizumab) / Roche
P2 data, Journal: Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial. (Pubmed Central) - Oct 3, 2024 P2 Larger, randomised trials are warranted to compare this low-toxicity, chemotherapy-free combinatorial regimen with standard chemotherapy. The atezolizumab, venetoclax, and obinutuzumab triplet combination was shown to be active and safe, suggesting that this chemotherapy-free regimen could become a new first-line treatment approach in patients with DLBCL-RT.
- |||||||||| Rituxan (rituximab) / Roche
Journal: Giant cell hepatitis associated with autoimmune hemolytic anemia: more evidence for B-cell depletion therapy for a rare immune mediated disease of infancy. (Pubmed Central) - Oct 3, 2024 In this issue, the report of a series of 20 children with GCH-AHA from Shanghai, China, confirms the previous treatment experiences of a greater efficacy in obtaining complete remission of RTX or RTX treatment regimens compared to conventional regimens, with a good safety. To date, published experience with this rare disease suggests that RTX should be considered the cornerstone of treatment for complicated or relapsing cases of GCH-AHA and given the increasing evidence on its efficacy and safety, RTX might be even an acceptable option as first line therapy beside conventional treatment, to drastically reduce the cumulative steroids exposure and its side effects.
- |||||||||| Sarclisa (isatuximab-irfc) / Sanofi
Journal: Isatuximab plus carfilzomib-dexamethasone for relapsed multiple myeloma. (Pubmed Central) - Oct 3, 2024 To date, published experience with this rare disease suggests that RTX should be considered the cornerstone of treatment for complicated or relapsing cases of GCH-AHA and given the increasing evidence on its efficacy and safety, RTX might be even an acceptable option as first line therapy beside conventional treatment, to drastically reduce the cumulative steroids exposure and its side effects. No abstract available
|